MedChemExpress LLC (MCE)

MedChemExpress - Model WS6 - 1421227-53-3

WS6 is an IkB kinase and EBP1 inhibitor, with IC50 values of 0.24 nM, 0.21 nM, and 40.48 nM in MV4-11, MOLM13, and K562 cells, respectively. WS6 promotes the proliferation of alpha and beta cells in the pancreas, has antioxidant and anti-inflammatory activities, and can alleviate depression like behavior in rats[1][2][4].

WS6

MCE China：WS6

Brand：MedChemExpress (MCE)

Cat. No.HY-12461

CAS：1421227-53-3

Purity：99.94%

Storage：Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year

Shipping：Room temperature in continental US; may vary elsewhere.

Description：WS6 is an IkB kinase and EBP1 inhibitor, with IC50 values of 0.24 nM, 0.21 nM, and 40.48 nM in MV4-11, MOLM13, and K562 cells, respectively. WS6 promotes the proliferation of alpha and beta cells in the pancreas, has antioxidant and anti-inflammatory activities, and can alleviate depression like behavior in rats[1][2][4].

In Vitro：WS6 (1 μM, 48 h) stimulates the proliferation of alpha and beta cells in human pancreatic islets while maintaining cell viability and beta cell differentiation phenotype[1]. WS6 (0-30 μM, 72 h) reduces MYCN protein stability and neuroblastoma tumorigenicity by inhibiting PA2G4 and MYCN protein binding[3]. WS6 (0-1 μM, 72 h) overcomes drug resistance and kills FLT3-ITD AML primitive cells by targeting FLT3-ITD driven kinase in acute myeloid leukemia (AML)[4]. WS6 (0.1, 0.5 μM, 15 min) promotes cell proliferation in the cochlea of neonatal mice by activating ERBB2 phosphorylation and PI3K activity, and enhancing EGFR family signaling[5]. WS6 exhibits better pharmacokinetic characteristics and binding strength with acetylcholinesterase and neurotrophic factors in computer simulations, thus having the potential to treat Alzheimer's disease[6].

In Vivo：WS6 (2.2 mg/kg; once a day; 28 days; i.p.) alleviates depression like behavior in rats by enhancing GABA signaling and dendritic density in the hippocampus of chronic unpredictable mild stress (CUMS) model rats[2].

IC50 & Target：EBP1, IkB[1]. In Vitro WS6 (1 μM, 48 h) stimulates the proliferation of alpha and beta cells in human pancreatic islets while maintaining cell viability and beta cell differentiation phenotype[1]. WS6 (0-30 μM, 72 h) reduces MYCN protein stability and neuroblastoma tumorigenicity by inhibiting PA2G4 and MYCN protein binding[3]. WS6 (0-1 μM, 72 h) overcomes drug resistance and kills FLT3-ITD AML primitive cells by targeting FLT3-ITD driven kinase in acute myeloid leukemia (AML)[4]. WS6 (0.1, 0.5 μM, 15 min) promotes cell proliferation in the cochlea of neonatal mice by activating ERBB2 phosphorylation and PI3K activity, and enhancing EGFR family signaling[5]. WS6 exhibits better pharmacokinetic characteristics and binding strength with acetylcholinesterase and neurotrophic factors in computer simulations, thus having the potential to treat Alzheimer's disease[6]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> WS6 Related Antibodies Western Blot Analysis[1]. Cell Line: Human pancreatic beta and alpha cells

References：

[1]. Boerner BP, George NM, Mir SU, Sarvetnick NE. WS6 induces both alpha and beta cell proliferation without affecting differentiation or viability. Endocr J. 2015;62(4):379-86. [Content Brief]

[2]. Zhang H, et al. WS6 Induces Adult Hippocampal Neurogenesis in Correlation to its Antidepressant Effect on the Alleviation of Depressive-like Behaviors of Rats. Neuroscience. 2021 Oct 1;473:119-129. [Content Brief]

[3]. Massudi H, et al. Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface. Cancers (Basel). 2023 Mar 17;15(6):1822. [Content Brief]

[4]. Bregante J, et al. Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia. Cancers (Basel). 2021 Dec 8;13(24):6181. [Content Brief]

[5]. Zhang J, et al. ERBB2 signaling drives supporting cell proliferation in vitro and apparent supernumerary hair cell formation in vivo in the neonatal mouse cochlea. Eur J Neurosci. 2018 Nov;48(10):3299-3316. [Content Brief]

[6]. Firdoos S, et al. In silico identification of novel stilbenes analogs for potential multi-targeted drugs against Alzheimer's disease. J Mol Model. 2023 Jun 14;29(7):209. [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
•   It has a professional experimental center and strict quality control and verification system；
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
•   The biological activity of the products has been verified by the experiments of customers in various countries；
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。